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INTRODUCTION:   
Dyslipidemia is the commonest cause of the blood vessel 
diseases and it leads to narrowing of lumen of arteries due 
to the sedimentation of lipid in their walls.
1,2
 Dyslipidemia 
occurs due to disturbance in the range of Total Cholesterol, 
LDL-C, VLDL, TGs and HDL-C.
1
 The incidence of this 
phenomenon is seen rising all over the world thereby 
increasing the morbidity and mortality due to 
cardiovascular diseases.
1,2
 NCEP-ATP III expert panel has 
set a goal to treat the dyslipidemic patients to minimize the 
risk who develop serious cardiovascular 
complications.
3
These goals can be achieved by proper 
treatment with lipid lowering drugs and improving the life 
style of the patients (NCEP-ATP III, 2002).
3
 A number of 
drugs e.g. statins, fenofibrate, niacin, ezetamibe, bile 
sequestrants etc. are used to treat this disorder.
2
 
The statins and fenofibrate have been widely studied and 
found least toxic, according to the studies conducted in the 
western countries.
1,2
 Few studies have been made in India 
and this study has been made keeping in view the people 
of North India especially the Punjabis of Majha-region 
because their socio-economic background and standard of 
living is quite different from the people of  Western 
countries.
4
 
The present study is meant to see the effects of the 
Rosuvastatin (newer statins) and Fenofibrate (as 
Superbioavailable tablet formulation) as monotherapy on 
the various parameters of lipid profile and goals achieved 
according to NCEP-ATP III guidelines. 
METHODOLOGY: 
This is a randomized, open-label, parallel study, conducted 
to assess the effects of Rosuvastatin (10 mg) and 
Fenofibrate (160 mg)  as monotherapy daily for 12 weeks, 
60 patients (30 in each group) of newly diagnosed 
dyslipidemic patients, aged 30-70 years, were selected 
visiting the OPD/ Wards of  Department of Medicine, 
Govt. Medical College, Amritsar. This study has already 
been approved by the Institutional Ethical Committee. 
Patient’s written consent was taken before the 
commencement of the study. Both the study drugs have 
been allocated among the patients randomly. The 
randomization has been achieved by using a Random 
Number Table.
5
Patients were evaluated at day 0, then at 6 
and 12 weeks for clinical examination, lipid profile and 
other parameters (Flowchart- I). 
Patients having hepatic, renal and thyroid disorder, 
Triglyceride > 600 mg/dl, already taking medication (like 
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hypolipidemics, oral contraceptive pills, corticosteroids), 
pregnant and lactating ladies and patients who were 
sensitive to the study drugs were excluded from the study.
 
Flowchart -I 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
Statistical Analyses:  The data were expressed as mean + 
standard deviation (SD) and mean percentage change. 
Treatment effects were tested with a paired student’s ‘t’ 
test for data. 
Patients Excluded 
-Not meeting the inclusion criteria  
-Not given the consent 
- Patients refused to come for follow up 
at regular intervals 
Randomization done to the selected patients 
Group II 
30 patients received allocated Fenofibrate 
Group I 
30 patients received allocated Rosuvastatin 
Group II 
Patients evaluated for clinical 
examination, blood investigation and 
adverse effects at 6 and 12 weeks 
None of the patient withdrew or left the 
medication 
 
 
Group I 
Patients evaluated for clinical 
examination, blood investigation and 
adverse effects at 6 and 12 weeks 
None of the patient withdrew or left the 
medication 
Group II 
At the completion of study results are 
expressed as mean with Standard 
deviation, mean percentage change and 
student’s ‘t’ test applied  
Group I 
At the completion of the study results 
are expressed as mean with Standard 
deviation, mean percentage change 
and student’s ‘t’ test applied  
Patients assessed for eligibility  
Patients come to the OPD/Ward 
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RESULTS: 
Baseline characteristics (Table I) and baseline levels of 
different parameters (Table II) of the group I and group II 
were compared at the start of therapy. The difference in 
both the groups was statistically insignificant (p>0.05) at 
baseline (0 day). Monotherapy of Rosuvastatin and 
Fenofibrate in group I and group II  showed significant 
changes of Total Cholesterol, triglycerides, LDL-C and 
HDL-C at 6 weeks and 12 weeks (Table III).  
In the category of Group I, CAD or CHD equivalent 
patients
3
 had shown more fall in the levels of LDL-C, and 
TC:HDL ratio as compared to total mean percentage fall in 
the group at 12 weeks, while less fall was noted in levels 
of LDL:HDL ratio (Table III and Table IV). While in 
group II, CAD or CHD equivalent patients had resulted in 
more fall in the levels of TGs and TC:HDL ratio as 
compared to total mean percentage fall, while slightly less 
fall was noted in the levels of LDL-C and LDL:HDL ratio 
(Table III and Table IV) as compared to total mean 
percentage in the group.  
 
 
 
 
   
 
Table III: Mean percentage change in the parameters at 6 weeks and 12 weeks 
 Group I  Group II 
Parameters 6 weeks  12 weeks   6 weeks 12 weeks 
T. Cholesterol -20.41% 
(p<0.001) 
 -35.79% 
(p<0.001) 
-15.64% 
(p<0.001) 
-25.60% 
(p<0.001) 
TGs -16.21% 
(p<0.001) 
-29.30% 
(p<0.001) 
-19.85% 
(p<0.001) 
-39.92% 
(p<0.001) 
LDL-C -27.47% 
(p<0.001) 
- 47.82% 
(p<0.001) 
-21.43% 
(p<0.001) 
-34.67% 
(p<0.001) 
HDL-C +7.69% 
(p<0.001) 
+18.75 
(p<0.001) 
+13.10% 
(p<0.001) 
+30.53% 
(p<0.001) 
TC:HDL ratio -23.20% 
(p<0.001) 
- 43.61% 
(p<0.001) 
-25.42% 
(p<0.001) 
-35.41% 
(p<0.001) 
LDL:HDL ratio -32.93% 
(p<0.001) 
-91.94% 
(p<0.001) 
-30.47% 
(p<0.001) 
-49.87% 
(p<0.001) 
   
 
Table I: Baseline Characteristics 
Variables Group I Group II 
Mean Age (years) 57.13 51.9 
Gender  
        Male  
        Female 
 
10 
20 
 
17 
13 
Waist circumference (cm) 
         Male   
         Female  
 
102.8 
93.8 
 
98.82 
102.38 
Diabetic 2 6 
Hypertensive 21 21 
CAD 11 11 
Post menopausal 17 5 
Alcoholic 6 8 
Table II: Baseline Parameters values 
Parameters  Group I Group II  p-value 
T. Cholesterol (mg/dl) 241.62 + 30.67 231.6 + 41.09 p>0.05 
TGs (mg/dl) 239.90 + 70.48 259.67 + 28.62 p>0.05 
LDL-C (mg/dl) 154.61 + 22.65 143.67 + 27.93 p>0.05 
HDL-C (mg/dl) 36.80 + 2.70 36.13 + 1.48 p>0.05 
*value in mean +S.D 
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Table IV: Mean percentage change in the parameters in CAD patients 
Parameters Group I Group II 
T. Cholesterol -38.10% 
(p<0.001) 
-24.84% 
(p<0.001) 
TGs -30.47% 
(p<0.001) 
-43.91% 
(p<0.001) 
LDL-C -52.11% 
(0.001) 
-32.37% 
(p<0.001) 
HDL-C +21.32% 
(p<0.001) 
+29.83% 
(p<0.001) 
TC:HDL ratio -49.03% 
(p<0.001) 
-41.89% 
(p<0.001) 
LDL:HDL ratio -60.64% 
(p<0.001) 
-47.82% 
(p<0.001) 
 
  
According to NCEP- ATP III criteria (NCEP- ATP III, 
2002), Group I and Group II achieved desired purpose for 
Total cholesterol (by 100% vs 93.33%), LDL-C (by 90% 
vs. 76.67%), TGs (by 26.67% vs 53.33%) and HDL-C (by 
40% vs. 60%) (Table V).  
  Among metabolic syndrome patients, both the 
groups achieved the set target for the components of 
metabolic syndrome (39.22% vs 41.66%), Triglycerides 
(52.94% vs. 57.14%), HDL-C (29.41% vs. 71.14%). The 
waist circumference also reduced by 12.50% in group II 
but not in group I (Table V).  
DISCUSSION 
Group I 
Rosuvastatin 10 mg per day in group I resulted in 
statistically significant fall in levels of serum TC, TGs, and 
LDL-C at 12 weeks (Table III). TC and LDL-C fall is 
slightly less as reported by CORALL study (33.2% and 
45.9%, and 37.1% and 50.6% at both 6 weeks and 12 
weeks)
 6
 while TGs level falls at 6 weeks (Table III) is 
slightly less, but at 12 weeks is more as revealed by 
CORALL study (18.8% and 23.7% respectively).
6
 
HDL-C level rises by 7.69% and 18.75% at 6 
weeks and 12 weeks [Table III] which are less as stated by 
Jayaram et al (+13.8 % at 6 weeks),
7
 but more as reported 
by Shepherd et al (+8 % at 12 weeks).
8
 
Table V: Goals achieved according to NCEP-ATP III criteria 
Parameters Group I Group II 
T. Cholesterol 100% 93.33% 
TGs 26.67% 53.33% 
LDL-C 90% 76.67% 
HDL-C 40% 60% 
Metabolic syndrome 39.22% 41.66% 
TGs* 52.94% 57.14% 
HDL-C* 29.41% 71.14% 
WC* Insignificant 12.50% 
*Target levels achieved in Metabolic syndrome patients according to NCEP-ATP III Criteria [TGs (< 150 mg/dl), HDL 
(M>40 mg/dl & F >50 mg/dl), *WC (Waist Circumference) (M<102 cm & F <88 cm )] 
 
Lipid ratios like TC:HDL  and LDL:HDL [Table 
III] fall is more as published by  Jayaram S et al, (39.8% 
and 47.42% at 6 weeks)
7
 and CORALL study (37.2% and 
50.3% at 12 weeks).
6 
In CAD or CHD equivalent patients (NCEP-
ATP III, 2002) Rosuvastatin results in significant fall in 
the levels of LDL-C, and TC:HDL ratio as compared to 
total mean percentage fall, while less fall is noted in 
levels of and LDL:HDL ratio [Table IV]. 
Rosuvastatin effectively achieves NCEP-ATP III 
goals for TC, TGs, LDL-C, HDL-C and also treats the 
components of metabolic syndrome [Table V].  
The LDL-C goal (Table V) achieved is slightly 
more as stated by PULSAR study  (68.8%)
9
 and Park JS 
et al (87.64%).
10
 While the Triglycerides goal (Table V) 
achieved is markedly less as recorded by PULSAR study 
(62.1%).
9 
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Group II 
Fenofibrate 160 mg per day resulted in 
statistically significant fall in levels of serum TC, TGs 
and LDL-C at both 6 and 12 weeks (Table III). The fall 
continued to show in the levels of TC and LDL-C as 
compared to TGs as accounted by McKenney et al, 
(11.2%, 9.1% and 28.1% respectively),
11
 whereas at 12 
weeks these levels falls (Table III) are more as reported 
byBairaktari ET et al, (16%, 26% and 18% 
respectively).
12 
TC and LDL-C fall levels at 6 weeks and 12 
weeks is more as reported by McKenney et al (11.2% and 
9.1% at 6 weeks)
11
 and Jones PH et al (12.6% and 5.3% 
at 12 weeks).
13 
TGs level falls is markedly less at 6 weeks as 
reported by McKenney et al, 2005 (28.1%) while more 
fall at 12 weeks as reported by Jones PH et al, 2010 
(31.9%).
13 
HDL-C level raised by Fenofibrate (Table III) 
are more as declared by McKenney et al  (+11.8% at 6 
weeks),
11
 and Steinmetz A et al, 1996 (+41.4% at 12 
weeks).
14 
Lipid ratio of TC:HDL  (Table III) is slightly 
less fall while fall in LDL:HDL ratio  (Table III) is more 
as stated by Steinmetz A et al,  (34.94% and 31.31% 
respectively) at 12 weeks.
14
 
In CAD or CHD equivalent patients Fenofibrate 
results in more fall in the level of TC: HDL ratio [Table 
III] as compared to total mean percentage fall, while less 
fall is noted in the levels of LDL-C  and LDL:HDL ratio 
[Table III].  
Fenofibrate also successfully achieves NCEP-
ATP III goals for TC, TGs, LDL-C, HDL-C and also 
treats the components of metabolic syndrome [Table IV]. 
Till date no study has so far been done to see the effects 
of lipid lowering agents on the goals achieved according 
to NCEP-ATP III criterion that is a must for the patients 
who have CAD or CHD equivalent patients for better 
therapy to prevent the serious complications of 
cardiovascular diseases (CVDs).  
Comparison of effectiveness of Rosuvastatin and 
Fenofibrate 
On comparing Rosuvastatin and Fenofibrate, it 
was found that Rosuvastatin is more effective in lowering 
TC, LDL-C and Lipid ratios (Table III). Rosuvastatin also 
results in more goals achievements for these parameters 
according to NCEP-ATP III criteria [Table V]. Thus 
Rosuvastatin is effective in a patient who has 
dyslipidemia with higher TC and LDL-C levels.While 
Fenofibrate resulted in significant decrease in TGs and 
raised HDL-C level as compared to Rosuvastatin [Table 
IV]. It also resulted in more goals achievements of 
NCEP-ATP III for TGs, HDL-C and Metabolic syndrome 
[Table V].  
It has been seen that both the drugs significantly 
achieved the set goals as per NCEP-ATP III for 
dyslipidemic patients. But their effects are variable on the 
different parameters of lipid profile. In Indian patients, 
there is higher incidence of hypertriglyceridaemia and 
lower levels of HDL-C,
4
 thus Fenofibrate is the drug of 
choice in these dyslipidemic patients. 
Clinical assessment and blood tests of the 
study’s patients had not shown any serious adverse 
effects during the trial, indicated that these drugs were 
well tolerated by those patients and none of the patients 
were withdrawn during it.  Mild side- effects were seen 
like myalgia (10% vs 5%) and  headache (6.66% vs 
3.33%) in Rosuvastatin and Fenofibrate respectively. 
Fenofibrate also led to nausea (6.66%) and constipation 
(3.33%).  
It has been observed that most of the people had 
concomitant other diseases like hypertension, coronary 
disease and diabetes mellitus and thus it 
becomesnecessary to treat these diseases along with 
dyslipidemia simultaneously otherwise high risk of 
developing cardiovascular complications is always there. 
Therefore, it is mandatory to treat the dyslipidemia at 
priority basis with the lipid lowering agents (statins or 
Fenofibrate). 
There is also a need to confirm the result on the 
basis of larger trial so that we could better treat the 
dyslipidemic patients according to India’s  socio-cultural 
scenario. 
In conclusion, monotherapy of Rosuvastatin and 
Fenofibrate in patients with dyslipidemia effectively 
improves the Lipid profile levels as both these agents had 
achieved the desired goal to treat the components of 
metabolic syndrome and other NCEP –ATP III targets as 
well.  
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